FDA reduces Lunesta starting dose

Share this article:

The Food and Drug Administration is requiring Sunovion to reduce the recommended starting dose for sleep drug Lunesta (eszopilcone) from 2mg to 1mg for both men and women.

The regulator announced Thursday that patients may end up using higher—as in 2mg or 3mg—doses if needed, but they should begin with 1mg because “higher doses are more likely to result in next-day impairment of driving and other activities that require full alertness.”

The FDA said the study of 91 patients found “severe next-morning psychomotor and memory impairment” that could impair driving skills, memory and coordination up to 11 hours after ingestion.

The FDA's notice adds that “patients were often unaware they were impaired.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.